{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:08:19Z","timestamp":1793833699504,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"P30","award":["AG12300"],"award-info":[{"award-number":["AG12300"]}]},{"name":"R01","award":["HD048179"],"award-info":[{"award-number":["HD048179"]}]},{"DOI":"10.13039\/100006663","name":"NIDRR","doi-asserted-by":"publisher","award":["H133A020526"],"award-info":[{"award-number":["H133A020526"]}],"id":[{"id":"10.13039\/100006663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jneuroim.2014.06.017","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T07:23:24Z","timestamp":1403853804000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Beta-amyloid auto-antibodies are reduced in Alzheimer's disease"],"prefix":"10.1016","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-817X","authenticated-orcid":false,"given":"Bao-Xi","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight C.","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Diaz-Arrastia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2014.06.017_bb0205","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neulet.2003.10.071","article-title":"Immune response to A\u03b2-peptides in peripheral blood from patients with Alzheimer's disease and control subjects","volume":"355","author":"Baril","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0045","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.biopsych.2004.12.008","article-title":"Decreased serum amyloid beta(1\u201342) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radio labeled amyloid beta(1\u201342) peptide","volume":"57","author":"Brettschneider","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0065","doi-asserted-by":"crossref","first-page":"12145","DOI":"10.1073\/pnas.0904866106","article-title":"Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease","volume":"106","author":"Britschgi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"261","key":"10.1016\/j.jneuroim.2014.06.017_bb0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Pericak-Vance MAGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"13","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0025","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0220","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/11533070-000000000-00000","article-title":"Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence","volume":"70","author":"Dodel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0135","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.4401-10.2011","article-title":"Naturally occurring autoantibodies against {beta}-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease","volume":"31","author":"Dodel","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0130","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","article-title":"Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity","volume":"126","author":"Du","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/187152710791012017","article-title":"Amyloid-\u03b2 immunotherapy for Alzheimer's disease","volume":"9","author":"Fu","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0125","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1096\/fj.09-150359","article-title":"High-molecular-weight \u03b2-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients","volume":"24","author":"Fukumoto","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0015","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2007.03.023","article-title":"Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to A\u03b2(25-35) oligomers, S100b and neurotransmitters","volume":"186","author":"Gruden","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1471-4159.2008.05477.x","article-title":"Antigen\u2013antibody dissociation in Alzheimer disease: a novel approach to diagnosis","volume":"106","author":"Gustaw","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0055","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ana.1061","article-title":"Autoantibodies to amyloid-beta and Alzheimer's disease","volume":"49","author":"Hyman","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0145","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jnr.20886","article-title":"Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide","volume":"84","author":"Istrin","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00401-008-0466-z","article-title":"Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?","volume":"117","author":"Jellinger","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00002093-200607000-00001","article-title":"Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease","volume":"20","author":"Jinaping","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archneur.1996.00550010045015","article-title":"Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study","volume":"53","author":"Klatka","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jneumeth.2010.01.018","article-title":"Measurement of anti-A\u03b21\u201342 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding","volume":"187","author":"Klaver","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0165","first-page":"1","article-title":"Function and comorbidities of apolipoprotein e in Alzheimer's disease","volume":"2011","author":"Leduc","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jmb.2003.11.019","article-title":"Effect of different anti-A\u03b2 antibodies on A\u03b2 fibrillogenesis as assessed by atomic force microscopy","volume":"335","author":"Legleiter","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00002093-200607000-00001","article-title":"Low avidity and level of serum anti A\u03b2 antibodies in Alzheimer disease","volume":"20","author":"Li","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0195","doi-asserted-by":"crossref","first-page":"e68996","DOI":"10.1371\/journal.pone.0068996","article-title":"Increased levels of antigen-bound \u03b2-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients","volume":"8","author":"Maftei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-2094-7-90","article-title":"Human intravenous immunoglobulin provides protection against A\u03b2 toxicity by multiple mechanisms in a mouse model of Alzheimer's disease","volume":"7","author":"Magga","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1369-1600.2012.00490.x","article-title":"The association between DRD2\/ANKK1 and genetically informed measures of alcohol use and problems","volume":"18","author":"Meyers","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0040","doi-asserted-by":"crossref","first-page":"17458","DOI":"10.1074\/jbc.M414176200","article-title":"Autoantibodies to redox-modified oligomeric A\u03b2 are attenuated in the plasma of Alzheimer's disease patients","volume":"280","author":"Moir","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1385\/NMM:3:1:29","article-title":"Autoantibodies to amyloid beta peptide (A\u03b2) are increased in Alzheimer's disease patients and A\u03b2 antibodies can enhance A\u03b2 neurotoxicity: implications for disease pathogenesis and vaccine development","volume":"3","author":"Nath","year":"2003","journal-title":"Neuromolecular Med."},{"issue":"11","key":"10.1016\/j.jneuroim.2014.06.017_bb0105","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"A\u03b2 species removal after A\u03b242 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0120","doi-asserted-by":"crossref","first-page":"16742","DOI":"10.1073\/pnas.262663499","article-title":"A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR","volume":"99","author":"Petkova","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.23857","article-title":"Anti-amyloid b autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies","volume":"73","author":"Piazz","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/bit.22367","article-title":"Kinetic study of \u03b2-amyloid residue accessibility using reductive alkylation and mass spectrometry","volume":"104","author":"Ramos","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","article-title":"Apolipoprotein E alleles as risk factors in Alzheimer's disease","volume":"47","author":"Roses","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0050","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2741\/3496","article-title":"Identification of autoantibody against beta-amyloid peptide in the serum of elderly","volume":"14","author":"Sohn","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0200","first-page":"867","article-title":"Elevation of \u03b2-amyloid 1-42 autoantibodies in the blood of amnestic patient with mild cognitive impairment","volume":"67","author":"Stordce","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","article-title":"Natural human antibodies to amyloid beta peptide","volume":"7","author":"Szabo","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"Weksler","year":"2002","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jb\/mvm239","article-title":"Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro","volume":"143","author":"Yoshihara","year":"2008","journal-title":"J. Biochem."},{"key":"10.1016\/j.jneuroim.2014.06.017_bb0180","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ntr\/ntp141","article-title":"DRD2-related TaqIA polymorphism modulates motivation to smoke","volume":"11","author":"Zuo","year":"2009","journal-title":"Nicotine Tob. Res."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281400188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281400188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:24:18Z","timestamp":1759047858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557281400188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":43,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S016557281400188X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.06.017","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-amyloid auto-antibodies are reduced in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}